Conferences

PartneringScientific and clinical experts from Vernalis regularly attend international conferences in drug discovery and related areas.

Conferences we have attended / will be attending include:

Partnering

  • 25–27 April 2016, BioTrinity London
  • 6–9 June 2016, BIO San Francisco
  • 13–15 September 2016, BIO Pharm America Boston

Scientific

 2016

  • 13-16 March 2016,  ACS San Diego
  • 19-22 April 2016, CHI Drug Discovery Chemistry, San Diego
  • 12-13 May 2016, GTCBio Drug Discovery, Berlin
  • 7-10 June 2016, 3rd NovAliX Biophysics Conference, Strasbourg
  • 12-13 June 2016, GTC Bio: 2nd Kinase Inhibitors Design & Screening, Berlin
  • 15-16 June 2016, Global Structural Drug Design Summit, Lisbon
  • 12-15 July FBDD Down-Under, Melbourne, Australia
  • 9-10 October 2016, FBLD2016, Cambridge, MA

2017

  • 6-7 March 2017, Drug Discovery, Selectbio, Cambridge, UK

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch